Scilex's Semnur Pharmaceuticals to go public through $2.5B SPAC merger as it advances sciatica prospect
Fierce Pharma
SEPTEMBER 3, 2024
Semnur Pharmaceuticals, which is working on a non-opioid prospect for sciatica, has agreed to merge with special purpose acquisition company Denali Capital Acquisition Corp. Semnur Pharmaceuticals is following in its parent company Scilex's footsteps with a special purpose acquisition company (SPAC) merger.
Let's personalize your content